Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Monday morning. The brokerage issued a hold rating on the medical research company’s stock.

Several other analysts have also recently issued reports on CTSO. B. Riley reiterated a buy rating and set a $3.00 target price on shares of Cytosorbents in a research report on Wednesday, May 15th. HC Wainwright reaffirmed a neutral rating and set a $1.00 price objective on shares of Cytosorbents in a report on Tuesday, May 7th.

Cytosorbents Trading Up 1.3 %

Shares of NASDAQ:CTSO opened at $1.20 on Monday. The stock has a 50 day moving average of $0.92 and a 200 day moving average of $0.93. The company has a market cap of $63.34 million, a PE ratio of -2.03 and a beta of 0.57. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $3.73. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.10.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $9.79 million during the quarter, compared to analyst estimates of $9.78 million. Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. During the same period in the prior year, the business posted ($0.17) earnings per share. As a group, equities research analysts expect that Cytosorbents will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Cytosorbents

Several large investors have recently modified their holdings of the stock. Key Client Fiduciary Advisors LLC raised its position in Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after purchasing an additional 22,557 shares during the period. Raymond James & Associates purchased a new stake in shares of Cytosorbents during the fourth quarter valued at $56,000. Sargent Investment Group LLC grew its holdings in shares of Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares during the last quarter. Avenir Corp increased its stake in Cytosorbents by 4.0% in the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after buying an additional 121,294 shares during the period. Finally, Neuberger Berman Group LLC lifted its holdings in Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 299,103 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.